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Abstract
Background—Methadone and buprenorphine are recommended to treat opioid use disorders 
during pregnancy. However, the literature on the relationship between longer-term effects of 
prenatal exposure to these medications and childhood development is both spare and inconsistent.
Methods—Participants were 96 children and their mothers who participated in MOTHER, a 
randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. The present 
study examined child growth parameters, cognition, language abilities, sensory processing, and 
temperament from 0–36 months of the child’s life. Maternal perceptions of parenting stress, home 
environment, and addiction severity were also examined.
Results—Tests of mean differences between children prenatally exposed to methadone vs. 
buprenorphine over the three-year period yielded 2/37 significant findings for children. Similarly, 
tests of mean differences between children treated for NAS relative to those not treated for NAS 
yielded 1/37 significant finding. Changes over time occurred for 27/37 child outcomes including 
expected child increases in weight, head and height, and overall gains in cognitive development, 
language abilities, sensory processing, and temperament. For mothers, significant changes over 
time in parenting stress (9/17 scales) suggested increasing difficulties with their children, notably 
seen in increasing parenting stress, but also an increasingly enriched home environment (4/7 
scales).
Conclusions—Findings strongly suggest no deleterious effects of buprenorphine relative to 
methadone or of treatment for NAS severity relative to not-treated for NAS on growth, cognitive 
development, language abilities, sensory processing, and temperament. Moreover, findings suggest 
that prenatal opioid agonist exposure is not deleterious to normal physical and mental 
development.
Keywords
opioid agonist medication; prenatal exposure; neonatal abstinence syndrome (NAS); early 
childhood development
1. Introduction
Methadone and buprenorphine, if taken in adequate doses, can stabilize pregnant women 
with opioid use disorder and prevent relapse (Hulse and O'Neil, 2002; Jones et al., 2010; 
Jones et al., 2006; Kaltenbach et al., 1998). However, concern is often raised regarding 
effects of such prenatal exposure to these medications on the developmental outcome of the 
children. Studies to date have produced inconsistent findings. A review by Maguire and 
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colleagues (Maguire et al., 2016) suggests that prenatal exposure to opioids may be 
associated with deficits in cognition, psychomotor, and behavioral processes in infants and 
young children. However, a review by Behnke and Smith (2013) found long-term effects on 
behavior but no consensus on cognition and suggest studies with positive findings were 
usually confounded by environmental factors. Most publications included in the reviews 
have concerning methodological limitations (e.g., conflating different opioid exposures, not 
controlling for tobacco and alcohol exposure) (Jones et al., 2015) and reported on cross-
sectional case-control studies in small, heterogeneous samples, with few prospective 
longitudinal studies (Konijnenberg and Melinder, 2011).
Systematic reviews and meta-analyses (Brogly et al., 2014; Zedler et al., 2016) have 
generally supported the contention that buprenorphine is superior to methadone in terms of 
neonatal outcomes. Zedler and colleagues (Zedler et al., 2016) concluded that prenatal 
exposure to buprenorphine relative to methadone has a lower risk of preterm birth, greater 
birth weight, and larger head circumference. Brogly and colleagues (Brogly et al., 2014) also 
report greater birth weight and larger head circumference as well as a higher mean 
gestational age and a lower risk for treatment for neonatal abstinence syndrome (NAS) and 
shorter length of hospital stay for buprenorphine than methadone-exposed neonates. 
Neonates treated for NAS had a shorter duration of NAS treatment and a lower total dosage 
of morphine dose in buprenorphine- than methadone-exposed neonates. Yet there are only 
two studies to date that compare the outcome of children prenatally exposed to 
buprenorphine to children prenatally exposed to methadone, both of which were 
retrospective pediatric clinical chart reviews at birth and 4 months of age (Bier et al., 2015) 
and through 2 years of age (Humbarger et al., 2016). To date, there are no studies that 
prospectively examine developmental outcomes of children prenatally exposed to 
buprenorphine compared to children prenatally exposed to methadone, although a 
longitudinal study assessed visual evoked potential scores at 4 months of age (Whitham et 
al., 2010) and at 3 years of age (Whitham et al., 2015) and found little difference between 
buprenorphine and methadone exposure.
The question of the long-term effect of NAS has recently received new emphasis given the 
rising opioid epidemic and the significant increase in prenatal opioid exposure (Patrick et al., 
2015). NAS has been used as an index of risk in recent legislation (Child Abuse Prevention 
Act (CAPTA) of 2010; the Comprehensive Addiction and Recovery Act (CARA) of 2016) 
resulting in potential consequences for mothers receiving opioid medication for treatment of 
OUD while pregnant. However, the only study that has examined if developmental outcome 
differs for infants who required treatment for NAS compared to infants who exhibited mid 
NAS and required no treatment found no difference in development at 6 months of age 
(Kaltenbach and Finnegan, 1986). There are no data regarding the effect of severity of NAS 
on development during late infancy and early childhood.
The primary interest of the present study was threefold. First, to determine whether changes 
in child growth parameters, cognition, language abilities, sensory processing, and 
temperament over the 36-month period were differentially related to prenatal buprenorphine 
versus methadone exposure. Significant results would indicate that the children develop 
differently over the first three years of life as a result of exposure to one of the two opioid 
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agonists. Second, to determine whether changes in child developmental outcomes over this 
36-month period were differentially related to treatment for NAS. Significant results would 
suggest that children who were treated for NAS as neonates develop differently over the first 
three years of life as a result of NAS severity and/or exposure to morphine treatment. Third, 
to determine the extent to which young children prenatally exposed to opioid agonist 
medication follow a normal course of development and the extent to which maternal 
perceptions of parenting stress, home environment, and addiction severity might have 
changed over the three-year period.
This study examined secondary outcomes of child growth parameters, cognitive 
development, language abilities, sensory processing, and temperament, and maternal 
perceptions of parenting stress, home environment, and addiction severity during the child’s 
first 36 months of life in a sample of 96 children and their mothers who participated in a 
randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. This study 
has multiple strengths relative to previous research: (1) the maternal sample is clearly 
defined by study eligibility criteria; (2) use of substances other than either methadone or 
buprenorphine during pregnancy was minimal; (3) both child and maternal functioning are 
examined; (4) the potentially adverse impact on development of neonatal abstinence 
syndrome (NAS) that requires treatment following prenatal exposure to either methadone 
and buprenorphine is examined; and (5) it is longitudinal and prospective.
2. Methods
2.1 Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study
Methodological aspects of the MOTHER trial relevant to this article, including the inclusion/
exclusion criteria and the CONSORT diagram, as well as maternal baseline characteristics 
and secondary neonatal and maternal outcomes (i.e., amount of prenatal care, positive drug 
screen at delivery, etc.) have already been published (Jones et al., 2012; Jones et al., 2010). 
MOTHER (Jones et al., 2010) was a double-blind, double-dummy, flexible-dosing, two-
group randomized controlled trial. Either methadone or buprenorphine was provided to 175 
opioid-dependent pregnant women with a singleton fetus (6–30 weeks), of whom 58 women 
in the buprenorphine and 73 in the methadone condition delivered an infant while enrolled in 
the study. Buprenorphine (2–32 mg) and methadone (20–140 mg) dosing followed a flexible 
dose protocol (Jones et al., 2010).
NAS assessment was performed for all infants for a minimum period of 10 days post-
delivery. The MOTHER NAS Scale (MNS) (Jones et al., 2010) measured NAS. 
Supplementary Material1 (Jones et al., 2010) and Table 2 in Weaver and colleagues (Weaver 
et al., 2014) provide MNS development and scoring principles. Jones and colleagues (Jones 
et al., 2010) provide rater training and inter-rater agreement information. The NAS treatment 
protocol was based on MNS scores. Neonates requiring pharmacotherapy were treated with 
oral morphine sulfate.
1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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2.2 Procedures
The present study was approved by the Institutional Review Boards of the participating sites: 
Brown University, Johns Hopkins University, The Medical University of Vienna, the 
University of Vermont, Thomas Jefferson University and the City of Philadelphia, Vanderbilt 
University, and Wayne State University. Study participants were recruited at study sites 
following completion of MOTHER participation. Examiners trained in developmental 
evaluations assessed infants and research staff assessed mothers. All assessments were 
conducted at the hospital sites and all examiners were blind to the maternal-infant 
Medication Condition.
2.3 Measures and assessment schedule
Measures were a multidimensional set of well-validated instruments that are widely used 
both for clinical diagnoses and research assessment, with child measures of developmental 
outcomes focusing on growth parameters, cognitive development, sensory processing, 
temperament, and language abilities. Maternal measures focused on perceptions of parenting 
stress, home environment, and addiction severity. Assessments were conducted when infants 
were 3, 6, 12, 24, and 36 months of age. Table 1 includes descriptions of measures and their 
assessment schedule. Because first enrollment in MOTHER occurred in May 2005 and the 
follow-up National Institute on Drug Abuse supplement award for this study was not 
received until Spring 2008, some infants were too old to be administered the assessment 
battery at the early ages, and the assessment battery was not administered to some infants at 
the later ages due to study close-out before they reached three years of age.
2.4 Statistical analyses
For all outcomes except child growth parameters, the statistical model had two fixed 
between-subject factors, Treatment (Buprenorphine v. Methadone), NAS Treatment (Treated 
v. not-Treated), and one fixed within-group factor for assessment Time point. [The Time 
effect could involve up to 5 levels (3 months v. 6 months v. 12 months v. 24 months v. 36 
months). Not all outcomes were measured on all occasions; for these latter outcomes, Time 
included only a subset of these 5 levels, as appropriate to the assessment schedule for that 
outcome (see Table 1).] The statistical model for the three growth parameters also includes a 
fixed effect for child Sex. A linear mixed model (Littell et al., 2006; Verbeke and 
Molenberghs, 2000) examined the main effects and their respective interactions, assuming 
the outcome measures were normally distributed. To maximize detection of differences 
associated with each test of significance, the Type I error rate was set to .05 for all main and 
interaction tests of significance. Post hoc testing for interaction effects involved testing 
simple interaction or simple main effects, followed by testing pairwise mean differences, as 
appropriate to the outcome (Kirk, 2013). Post hoc testing for the Time main effect involved 
testing for linear trend and deviations from linearity to determine if change over time 
followed a systematic linear or non-linear progression or retrogression, with the spacing for 
the polynomial determined by the month of assessment, given the assessments were not 
conducted with equal intervening lengths of time. Sidak’s adjustment (Kirk, 2013; Šidák, 
1967) was applied to all post hoc tests. All analyses were performed with SAS version 9.3.
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There were three effects of interest for all outcomes: Medication Condition X Time 
interaction, NAS Treatment X Time interaction, and the Time main effect. The Medication 
Condition X Time interaction tested whether the change over the three-year period differed 
between the Buprenorphine and Methadone conditions. The NAS Treatment X Time 
interaction tested whether the change over the three-year period differed between the 
Treated- and not- Treated-for-NAS groups (for the child in the case of child outcomes and 
for the mothers in the case of maternal outcomes, respectively). The Time main effect tested 
for change over the three-year period, and assessed the general growth and development of 
the children. The associated tests for linearity assessed whether change in the outcome 
measure over time was uniform (e.g., followed a uniform or straight-line pattern).
Therefore, Other Effects, discussed in the Results, refer to those effects other than the 
Medication Condition X Time interaction effect, the NAS Treatment Group X Time 
interaction effect, and the Time main effect.
The principal focus in this study was on the child measures, as there was no research basis to 
expect maternal effects. Maternal effects were examined to help contextualize child 
differences, particularly to the extent the latter changed over time.
2.5 Minimum detectable effect size
To provide some context for examining results in addition to P values, we calculated the 
minimum detectable effect size, f2 (Cohen, 1988), for each effect in the statistical model. 
Table 2 displays the resulting effect size estimates f2.
3. Results
3.1 Participants
This subsample largely reflects the MOTHER sample as a whole. The maternal participants 
were relatively young [M=26.1 (SD=5.4)], with 75/96 (78%) less than 30 years of age], 
majority White [90/96 (94%)], with 39/96 (41%) having less than a high school education 
[years of education M=11.5 (SD=2.1)], largely unemployed [76/96 (79%)] and never 
married [71.96 (74%)]. They were maintained on their agonist medication as part of study 
participation for almost 20 weeks [M=143.7 (SD=41.4) days in the buprenorphine condition, 
M=136.0 (SD=57.7) days in the methadone condition, p>.4]. Overall, neonates were healthy 
[5-minute Apgar M=9.1 (SD= .9), with 3/96 (3%) having a 5-minute Apgar ≤ 7], only 8/96 
(8%) born prior to early term [estimated gestational age at delivery M=38.8 (SD=2.0)]. In 
addition, 54/96 (56%) neonates were treated for NAS; for these 54 neonates, NAS treatment 
lasted for an average of almost two weeks [M=16.9 (SD=15.4)]. Of the original 131 
MOTHER participants, 52/73 methadone and 44/58 buprenorphine condition participants 
provided longer-term follow-up data, p>.5. Relative to present study non-participants, study 
participants were more likely to be White (94% v. 71%, p< .001), less likely to be 
unemployed (79% v. 99%, p= .013), with neonates with a higher mean 5-minute Apgar 
[M=9.1 (SD= .9) v. M=8.5 (SD=1.3), p< .002], later mean gestational age at delivery 
[M=38.8 (SD=2.0) v. M=37.4 (SD=2.9), p< .002], and a shorter mean duration of NAS 
treatment [M=13.2 (SD=10.9) v. M=31.4 (SD=21.3), P< .001].
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3.2 Outcomes
The data reported in this paper are unique because they present findings on the largest and 
most comprehensive assessment of neonates prenatally exposed to agonist medications, with 
minimal to no additional drug exposure. Thus, a set of Supplementary Tables2 for child and 
maternal outcomes are included. These tables contain the test statistics and P values and the 
associated estimated marginal means and 95% confidence intervals for all effects except the 
Medication Condition X NAS Treatment and Medication Condition X NAS Treatment 
Group X Time interactions.
3.2.1 Child results
3.2.1.1 Medication Condition X Time Effects: There were two significant Medication 
Condition X Time interaction effects.
3.2.1.2 Receptive-Expressive Emergent Language Test – Third Edition: The Medication 
Condition X Time interaction effect was significant for the REEL-3 Receptive Percentile 
Rank. Means showed a distinct pattern in which the percentile rank mean for the 
Buprenorphine Condition was significantly lower than the percentile rank mean for the 
Methadone Condition at 12 months [M=28.8 (SE=5.9) v. M=45.9 (SE=5.0), respectively, p<.
03], with percentile rank means of the two conditions rising and closing with each other at 
24 [M=70.9 (SE=4.4) v. M=60.2 (SE=4.5), respectively, p>.09] and 36 months [M=67.2 
(SE=4.9) v. M=64.5 (SE=4.1), respectively, p>.66] (see Supplementary Table S33).
3.2.1.3 Infant Behavior Questionnaire Revised: The Medication Condition X Time 
interaction effect was significant for the IBQ-R Approach scale, largely due to the fact that 
the Buprenorphine Condition mean was significantly lower than the Methadone Condition 
mean at 3 months [M=4.1 (SE=0.2) v. M=5.0 (SE=0.3), respectively, p=< .03, while the 
means of the two conditions at 6 [M=5.5 (SE=0.2) v. M=5.3 (SE=0.2, respectively, p>.5] and 
12 months [M=6.0 (SE=0.2 v. M=6.1 (SE=0.2), respectively, p=>.8] were not significantly 
different from one another (see Supplementary Table S33).
3.2.2 NAS Treatment Group X time effects—There was one significant NAS 
Treatment Group X Time interaction effect.
3.2.2.1 Infant Behavior Questionnaire Revised: The NAS Treatment Group X Time 
interaction effect was significant for the IBQ-R Distress to Limitations scale. Examination of 
the means showed that the Treated-for-NAS group means were higher than the not-Treated-
for-NAS group at 6 months [M=3.9 (SE=0.2) v. M=3.3 (SE=0.3), respectively, p< .05] but 
not at 3 [M=3.7 (SE=0.2) v. M=3.3 (SE=0.3), respectively, p=>.2] and 12 months [M=4.1 
(SE=0.2) v. M=4.4 (SE=0.2), respectively, p>.2] (see Supplementary Table S33).
2Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
3Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi …
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3.2.3 Time main effects—Test statistics, P values, and the estimated marginal means and 
their 95% confidence intervals for the Time main effect for growth parameters are given in 
Table 3 for growth parameters and in Table 4 for developmental outcomes.
3.2.3.1 Growth parameters: Mean z-scores for weight, height, and head circumference 
increased from 3 to 36 months (see Table 3). Beginning below the 50th percentile at 3 
months and ending exceeding the 50th percentile at 36 months – and, in the case of weight 
and head circumference, significantly higher than the 50th percentile.
3.2.3.2 BSID-III: The Time effect was significant for nine of 10 BSID-III scales, the 
exception being the General Adaptive Percentile Rank Score (see Table 4). Changes over the 
period from 6 to 36 months for these nine scales could not be considered consistent (see 
Supplementary Table S64 for tests of linearity) – the only exception being the Cognitive 
Percentile Rank Score, which showed a general decline over the time period. However, six 
of the nine significant scales - excepting Motor Composite and General Adaptive Composite 
Scores and Social-Emotional Percentile Ranks – showed non-uniform change (see 
Supplementary Table S64 for tests of deviations from linearity), with means reflecting a 
weak decline and then a general upturn in scores at 36 months.
3.2.3.3 REEL-3: Three of the five REEL-3 measures showed significant changes over Time- 
the two Receptive Scores and the combined Language Ability Score (see Table 4). All three 
measures showed non-uniform changes over the period from 12 to 36 months (see 
Supplementary Table S64). Examination of the means suggested an increase in mean scores 
for the three significant measures from 12 to 24 months, leveling off from 24 to 36 months.
3.2.3.4 ITSP: Only two of four significant ITSP scales – Sensation Avoiding and Low 
Threshold – showed significant change over Time (see Table 4) that could be seen as 
showing a consistent pattern or as deviations from a consistent pattern of change (see 
Supplementary Table S65). For both scales, change was non-uniform. Examination of the 
means indicated that for both scales, there was a pronounced change from 6 to 12 months, 
flattening out at 24 months, and then an increase at 36 months.
3.2.3.5 IBQ-R: Of the 14 IBQ-R scores, eight tests of Time were significant (see Table 4). 
Seven of these eight scales showed consistent increases from 3 to 12 months (see 
Supplementary Table S65). In contrast, Cuddliness showed a consistent decline over this 
period. The rate of change for Activity Level rose from 3 to 6 months, and remained 
unchanged from 6 to 12 months.
3.2.4 Other effects—There were three significant Other Effects: One Sex X NAS 
Treatment Group interaction effect, one NAS Treatment Group main effect, and two 
significant Medication Condition X NAS Treatment effects.
4Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
5Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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3.2.4.1 Growth parameters: There was a significant Sex X NAS Treatment Group 
interaction effect for head circumference, although the means were found not to significantly 
differ from each other, with all ps>.05 The pattern of means would suggest that the 
interaction arose due to the fact that girls had a slightly larger head circumference in the not-
Treated-for-NAS group [M=0.47 (95% CI: −0.08, 1.03), Percentile= .61] than in the 
Treated-for-NAS group [M=−0.17 (95% CI: −0.54, 0.20), Percentile=.45], while boys had 
slightly larger head circumference in the Treated-for-NAS group [M=0.24 (95% CI: −0.18, 
0.65), Percentile=.56] than in the not-Treated-for-NAS group [M=−0.20 (95% CI: −0.62, 
0.23), Percentile=.47].
3.2.4.2 Infant Toddler Sensory Profile: The NAS Treatment Group main effect was 
significant for the ITSP Sensation Seeking scale, with the not-Treated-for-NAS group mean 
significantly higher than the mean for the Treated-for-NAS group.
3.2.4.3 Infant Behavior Questionnaire Revised: The Medication Condition X NAS 
Treatment interaction effect was significant for IBQ-R Distress to Limitations and Sadness 
scales. Examination of the means for the IBR-Q Distress to Limitations scale indicated that 
the only significant mean difference was that the mean for the Treated-for-NAS group was 
larger than the mean of the not-Treated-for-NAS group. For the Sadness scale, the four 
means were not found to be significantly different from one another. The pattern of means 
would suggest that the interaction arose due to the fact that the not-Treated-for-NAS group 
had a smaller mean than did the Treated-for-NAS group in the Methadone condition, while 
the not-Treated-for-NAS group had a larger mean than did the Treated-for-NAS group in the 
Buprenorphine condition.
3.2.5 Supplementary Results—Supplementary Table S16 contains the test statistics and 
P values for the child growth parameters while Supplementary Table S26 contains the test 
statistics and P values for the cognition, language abilities, sensory processing, and 
temperament. Supplementary Table S36 contains the associated estimated marginal means 
and 95% confidence intervals for these latter outcomes for all effects except the Medication 
Condition X NAS Treatment and Medication Condition X NAS Treatment Group X Time 
interactions.
3.2.6 Maternal results
3.2.6.1 Medication Condition X time effects: There was one significant Medication 
Condition X Time interaction effect.
3.2.6.2 Addiction Severity Index: Examination of the means for the ASI Legal composite 
score indicated a general pattern in which the means for both conditions fell off over the 
period from 3 to 36 months (Ms=0.03, 0.08, 0.01, 0.00, and 0.01 for the Buprenorphine 
condition respectively and Ms=0.10, 0.13, 0.10, 0.12, and 0.05 respectively for Methadone 
condition), but the Buprenorphine condition had significantly lower mean scores at 12 and 
24 months than did the Methadone condition [M= .01 (SE=.03) v. M=.10 (SE=.03) at 12 
6Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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months respectively, p<.03; M=.00 (SE.03) v. M= .12 (SE=.03) at 24 months respectively, 
p<.002] (see Supplementary Table S57).
3.2.6.3 NAS Treatment Group X time effects: There was one significant NAS Treatment 
Group X Time interaction effect.
3.2.6.4 Addiction Severity Index: The ASI Legal composite score showed significant 
differences between the means of Time within the not-Treated-for-NAS group [Ms=0.08, 
0.15, 0.07, 0.05, and 0.01, respectively; F(4,69)=4.2, p<.005}, but not for the means of Time 
within the Treated-for-NAS group [Ms= 0.05, 0.05, 0.05, 0.06, and 0.05, respectively; 
F(4,69)=0.2, p>.9] (see Supplementary Table S57).
3.2.7 Time main effects—Table 5 presents the test statistics, P values, and the estimated 
marginal means and their 95% confidence intervals for the Time main effect for all maternal 
outcomes.
3.2.7.1 PSI: PSI scores showed significant changes for nine of seventeen scales over Time, 
largely indicative of increased stress from child behaviors as the child enters the toddler 
stage and corresponding stress associated with parenting competence (see Table 5).
3.2.7.2 HOME: HOME scores showed significant changes for four of seven scales over 
Time (see Table 5), with scores rising from 6 to 24 to 36 months for those variables that 
were significant, as seen in the HOME total score (see Table 5).
3.2.7.3 ASI: There was no significant change over Time for the ASI composite scores (see 
Table 5).
3.2.8 Other Effects—There were 14 significant Other Effects. 3.2.8.1 Parenting Stress 
Index. There was a significant main effect for NAS Treatment Group for the PSI Reinforces 
Parent scale, with the mean for the Treated-for-NAS group significantly higher than the 
mean for the not-Treated-for-NAS group. There were significant Medication Condition X 
NAS Treatment Group interaction effects for the PSI Adaptability and Health scales. The 
PSI Adaptability mean was significantly higher for mothers in the Methadone condition 
whose neonates were Treated-for-NAS than the mean for the mothers in the Methadone 
condition whose neonates were not-treated-for-NAS, while the remaining three tests of the 
mean differences were nonsignificant. Regarding the PSI Health scale, post hoc testing 
indicated all simple mean differences were nonsignificant. There was a significant 
Medication Condition X NAS Treatment Group X Time interaction effect for the PSI Health 
scale. The simple interaction of Medication Condition X NAS Treatment at each level of 
Time was only significant at 6 months; however, none of the mean differences at 6 months 
were significant.
7Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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3.2.8.2 Home Observation for Measurement of the Environment: There was a significant 
Medication Condition main effect for HOME Organization, with the mean of the 
Buprenorphine condition significantly higher than mean for the Methadone condition.
3.2.8.3 Addiction Severity Index: There were significant Medication Condition main 
effects for the ASI Alcohol and Legal composite scores. For Alcohol, the Buprenorphine 
condition mean was significantly larger than the Methadone condition mean, while for 
Legal, the Buprenorphine condition mean was significantly smaller than the Methadone 
condition mean. There were significant NAS Treatment group main effects for the ASI 
Employment and Family/Social composite scores. For both ASI composite scores, the 
Treated-for-NAS group means were significantly larger than the not-Treated-for-NAS group 
means. The Medication Condition X NAS Treatment group interaction effect was significant 
for the ASI Medical composite score. The mean for the mothers whose neonates were 
Treated-for-NAS was significantly higher than the mean for the mothers whose neonates 
were not-treated-for-NAS, while the remaining tests of differences between the means were 
non-significant. The Medication Condition X NAS Treatment X Time interaction effect was 
significant for both the ASI Medical and Alcohol composite scores. For the Medical 
composite, the interaction was due to the fact that the means for both the Treated-for-NAS 
and not-Treated-for-NAS groups in the Buprenorphine condition rose over the three-year 
period, while this was not the case in the Methadone condition. In contrast, the interaction 
for the Alcohol composite was due to the fact that the means at 6 months was substantially 
lower in both the Treated-for-NAS and not-Treated-for-NAS groups in the Buprenorphine 
condition than the corresponding means in the Methadone condition
3.2.9 Supplementary results—Supplementary Table S48 contains the test statistics and 
P values for maternal parenting stress, home environment, and addiction severity measures. 
The estimated marginal means and 95% confidence intervals for all effects except the 
Medication Condition X NAS Treatment and Medication Condition X NAS Treatment 
Group X Time interactions are reported in Supplementary Table S5.
4. Discussion
Overall, this study found that from 3 months through 36 months of age, children prenatally 
exposed to buprenorphine or methadone were well within the range of normal development 
in physical growth measures, cognitive development and language development. Also, 
mothers maintained on buprenorphine or methadone did not differ on any of the measures, 
other than the ASI legal section.
4.1 Child findings
In this study, up to 36 months, children follow a path of normal development. Thus, findings 
for growth parameters suggest that prenatal opioid agonist exposure does not affect normal 
physical development. Conclusions are similar in terms of cognitive development, language 
abilities, sensory processing, and temperament. Changes over time in some, though not all 
8Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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Bayley mean composite scale and percentile rank scores as well as the ITSP scale scores, 
with a general upturn in scores at 36 months, argue against any conclusion of some overall 
pattern of loss of abilities in these areas.
Moreover, significant changes over time in the mean scores did not indicate any substantive 
developmental decline. Mean scores continued to be within the average range. The changes 
in language ability found in the Bayley language composite scale indicate that language 
development was within normal limits.
There are two significant Medication Condition X Time and one significant NAS Treatment 
Group X Time interaction, out of 37 such tests conducted for each effect. These results offer 
strong support for two conclusions. First, there is no apparent pattern of results that would 
argue for differential impact of prenatal exposure to methadone or buprenorphine on early 
childhood growth and development. Second, NAS severity does not have an adverse impact 
on early childhood growth and development. This finding is consistent with a previous study 
in neonates prenatally exposed to methadone (Kaltenbach and Finnegan, 1987) and provides 
important contemporary information for clinicians and policymakers.
4.2 Maternal findings
Maternal findings strongly indicated that, on average, neither methadone and buprenorphine 
mothers nor the mothers whose neonate was or was not treated for NAS differed from each 
other in terms of any characteristic over the three-year period, with the possible exception of 
ASI-defined legal problems. Scores on the PSI would suggest that the mothers, as a group, 
reported increasing difficulties with their children over the three-year period, notably seen in 
increasing Child Domain mean scores and increases in the parental competence mean score. 
It is unclear whether the children actually exhibit more challenging behaviors; whether 
mothers who experience high levels of parenting stress rate typical child behaviors as more 
severe; or whether the relationship is bi-directional. In contrast to the PSI findings, HOME 
scores show a consistently more enriched home environment over the period from 6 to 36 
months. Taken together, these results counteract the assumption that mothers with a history 
of opioid use disorder are unable to create a positive home environment (Kaltenbach, 2013) 
and suggest that developmental risk for their children may be related more to problems in 
the parent-child relationship.
4.3 Limitations
The study has several limitations. First, only 96 of the 131 women who participated in the 
MOTHER trial were recruited. While the subsample appears to be largely representative of 
the MOTHER sample, it is possible that unknown factor(s) may have operated to impact 
subsampling that may have biased the findings. Second, constraints placed on sampling due 
to cost and time limitations led to not all of the 96 mothers and their children being 
measured at each time point. Further, this sample size limited the statistical model 
complexity (e.g., no control for recruitment site, for child variables, or maternal covariates). 
Third, the MOTHER study emphasized internal, not external, validity, so the ability to 
generalize the current findings may be limited. However, the MOTHER sample was unique 
in that, with the exception of tobacco, there was minimal to no concomitant prenatal 
Kaltenbach et al. Page 12
Drug Alcohol Depend. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
substance exposure, including alcohol. Fourth, the subsample of MOTHER mothers and 
infants examined in this paper may differ in important ways from the MOTHER women and 
infants who were non-participants. Inclusion of non-participants could have impacted 
findings in unknown ways. Fifth, there was no comparison group of mother and children 
whose mothers were of similar socioeconomic status who did not use psychoactive 
substances. Lastly, the per-comparison α was set at .05, and as a result, the cumulative error 
rate in the study may be sizeable, with some unknown number of findings Type I errors. 
However, α was set at .05 in order to maintain our ability to detect relatively weaker 
medication and NAS treatment effect differences- effect sizes determined to be in the small-
to-medium range (see Table 2). Setting α to some value lower than .05 would have 
prevented detection of weaker relationships that might prove important to examine in future 
research.
5. Conclusions
The present study is the first longitudinal study to examine early childhood developmental 
outcomes of infants born to pregnant women who were enrolled in a randomized, controlled 
trial examining maternal treatment with methadone or buprenorphine with rigorous 
assessment and treatment protocols for NAS. Findings suggest that children prenatally 
exposed to opioid agonist medications follow a pattern of normal development during the 
first three years of life. These results are consistent with studies that find no differences in 
development between infants prenatally exposed to opioids and non-exposed infants. They 
also provide important comparison data to studies that have reported differences as such 
studies have all been confounded by multiple illicit and licit drugs.
Findings strongly suggest no deleterious effects for buprenorphine relative to methadone. 
Findings also strongly indicate no deleterious effects for NAS requiring treatment relative to 
not-treated-for-NAS in children 0–3 years old prenatally exposed to opioid agonist 
medication as part of a randomized controlled trial. Over the first three years, mothers in 
general struggled with parenting skills at the same time they reported they were able to 
provide an increasingly enriched home environment to address child needs. Findings suggest 
future research could profitably focus on intervention trials that examine the impact of 
parenting practices and parent training on the development of children who are prenatally 
exposed to opioid agonist medications.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Children exposed to opioids in utero exhibit normal development in early 
childhood
• There was no difference in development between methadone and 
buprenorphine exposure
• Neonatal Abstinence Syndrome (NAS) severity did not have an effect on early 
childhood growth and development
Kaltenbach et al. Page 16
Drug Alcohol Depend. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kaltenbach et al. Page 17
Table 1
Assessment Instruments and Assessment Schedule
Assessment
Time Point
(month)
Child Measures
Growth Measurements: Weight (gm), Height (in), Head Circumference (cm) (See Table 2 for an explanation of the 
transformation of these outcomes for purposes of analysis.)
3, 6, 12, 24, 36
Bayley Scale of Infant Toddler Development III (BSI-III):25 The BSI-III provides an extremely thorough, standardized 
assessment of infant development. In the present paper we report Cognitive, Language, Motor, Social-Emotional, and 
Adaptive Behavior scores. The composite scores are norm-referenced and standardized with a mean of 100 and a standard 
deviation of 15.
6, 12, 24, 36
Receptive-Expressive Emergent Language (REEL)-3:26 The REEL-3 is a 66-item, norm-referenced test administered to 
caregivers, developed to identify young children who have developmental problems in use or understanding of language. It is 
composed of two subtests, for emerging receptive and expressive language skills. The present paper reports on the Receptive 
and Expressive Ability scores and percentile ranks, and the Language Ability scores. The three Ability scores are scored 
according to population norms, in a manner similar to intelligence tests, with means of 100 and standard deviations of 15.
12, 24, 36
Infant Toddler Sensory Profile (ITSP):27 A standardized instrument for assessing a child’s sensory processing abilities and to 
profile the effect of sensory processing on functional performance in daily life. There are 36 items for children 0–6 months, 
and 48 items for children 7–36 months. There are four quadrants: Low Registration (13 items for 0–6 month form; 11 items 
for 7–36 month form), Sensation Seeking (6; 14), Sensory Sensitivity (12; 11), and Sensation Avoiding (5; 12), and a Low 
Threshold score representing a sum of the Sensory Sensitivity and Sensation Avoiding quadrant scores. Quadrant scores are 
computed by summing the responses to each item on a 5-point scale, ranging from 1 (“Almost always”) to 5 (“Almost 
never”), so that lower scores indicate relatively more functional problems in a given area of sensory processing.
3, 6, 12, 24, 36
Infant Behavior Questionnaire Revised (IBQ-R):28,29 A 91-item inventory of infant behavior in 14 domains: Activity Level; 
Distress to Limitations; Fear; Duration of Orienting; Smiling and Laughter; High Intensity Pleasure; Low Intensity Pleasure; 
Soothability; Falling Reactivity/Rate of Recovery from Distress; Cuddliness; Perceptual Sensitivity; Sadness; Approach; and 
Vocal Reactivity. Respondents score the frequency of infant behavior on a scale of 1 (“Never”) – 7 (“Always”). Scores on 
each domain are the mean of the item ratings in that domain, so in some cases, higher scores indicate more of a negative 
behavior (eg, Fear) while in other cases, higher scores indicate more of a positive behavior (eg, Cuddliness).
3, 6, 12
Maternal Measures
Parenting Stress Index (PSI):30 A 120-item inventory of parental stress in three domains: Child, with 6 subscales 
(Distractibility/Hyperactivity, Adaptability, Reinforces Parent, Demandingness, Mood, and Acceptability) that measures 
sources of stress from child behavior, as reported by the parent; Parent, with 7 subscales (Competence, Isolation, Attachment, 
Health, Role Restriction, Depression, and Spouse/Parenting Partner Relationship) that measure sources of stress related to 
parent functioning; and a Life Stress scale that measures the amount of parent stress caused by situational factors other than 
from the child or parent. The Child and Parent domains combine to yield the Total Stress scale. The 101 Child and Parent 
items are each scored on a 5-point scale (1 “Strongly Agree” – 5 “Strongly Disagree”), with the 19 Life Stress item responses 
indicating whether the events have occurred (0 “No” 1 “Yes:) in the past 12 months. Higher scores for each subscale and the 
two domain scores and the total score reflect more stress in that area.
3, 6, 12, 24, 36
Infant Toddler Home Observation for Measurement of the Environment (ITHOME):31 A 45-item inventory measuring 6 
domains of the home environment important to child development: Responsivity (11 items) Acceptance (8), Organization (6), 
Learning Materials (9), Involvement (6), and Variety (5). Each domain has a separate score ranging from 0 to the number of 
items in the respective scale; the domain scores are then added to yield a Total Score (range: 0–45), with higher scores 
indicating a relatively more enriched home environment.
6, 24, 36
Addiction Severity Index (ASI):32 A clinical assessment of addiction severity that measures functioning in 7 areas of the 
respondent’s life: Medical, Employment, Drug, Alcohol, Legal, Family/Social, and Psychiatric. Items from each section are 
weighted and contribute to a composite score for each area, with scores ranging from 0–1, with higher scores indicating 
greater problem severity.
3, 6, 12, 24, 36
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Table 2
Estimates of Effect Size f2 for Effects in the Inferential Statistical Model for 3, 4, and 5 Occasions of 
Measurement for N= 96 observations, α=0.05, and power (1−β)=0.80
Number of Measurement Occasions
3 4 5
Effect
Medication Condition (M) .104 .119 .131
Treated-for-NAS Group (N) .104 .119 .131
Time (T) .065 .071 .070
M × N .104 .119 .131
M × T .065 .071 .070
N × T .065 .071 .070
M × N × T .065 .071 .070
Note. Effect Size f2 was estimated using the set correlation method. See text for details.
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